491 related articles for article (PubMed ID: 25542821)
21. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
22. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
Garnock-Jones KP; Duggan ST
Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
[TBL] [Abstract][Full Text] [Related]
23. Ulipristal acetate: in uterine fibroids.
Croxtall JD
Drugs; 2012 May; 72(8):1075-85. PubMed ID: 22568731
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.
Gemzell-Danielsson K; Heikinheimo O; Zatik J; Poka R; Rechberger T; Hudecek R; Petersdorf K; Ramirez F; Faustmann T; Groettrup-Wolfers E; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():7-14. PubMed ID: 32559602
[TBL] [Abstract][Full Text] [Related]
25. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
27. Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding.
Arendas K; Leyland NA
J Obstet Gynaecol Can; 2016 Jan; 38(1):80-3. PubMed ID: 26872761
[TBL] [Abstract][Full Text] [Related]
28. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study.
Yerushalmi GM; Gilboa Y; Jakobson-Setton A; Tadir Y; Goldchmit C; Katz D; Seidman DS
Fertil Steril; 2014 Feb; 101(2):496-500. PubMed ID: 24220703
[TBL] [Abstract][Full Text] [Related]
29. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
31. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
32. Effects of long-term intermittent pharmacological therapy with ulipristal acetate on reducing the volume of uterine fibroids and relieving symptoms.
Kyeong HK; Choi J; Na YJ; Kim HG
Minerva Obstet Gynecol; 2023 Jun; 75(3):236-242. PubMed ID: 36786781
[TBL] [Abstract][Full Text] [Related]
33. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C
Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839
[TBL] [Abstract][Full Text] [Related]
34. Safety after extended repeated use of ulipristal acetate for uterine fibroids.
Fauser BC; Donnez J; Bouchard P; Barlow DH; Vázquez F; Arriagada P; Skouby SO; Palacios S; Tomaszewski J; Lemieszczuk B; William AR
PLoS One; 2017; 12(3):e0173523. PubMed ID: 28267814
[TBL] [Abstract][Full Text] [Related]
35. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
36. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment.
Courtoy GE; Donnez J; Marbaix E; Dolmans MM
Fertil Steril; 2015 Aug; 104(2):426-34.e1. PubMed ID: 26003270
[TBL] [Abstract][Full Text] [Related]
37. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
38. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
Luyckx M; Squifflet JL; Jadoul P; Votino R; Dolmans MM; Donnez J
Fertil Steril; 2014 Nov; 102(5):1404-9. PubMed ID: 25241376
[TBL] [Abstract][Full Text] [Related]
39. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis.
Kalampokas T; Kamath M; Boutas I; Kalampokas E
Gynecol Endocrinol; 2016; 32(2):91-6. PubMed ID: 26572056
[TBL] [Abstract][Full Text] [Related]
40. Influence of Ulipristal Acetate Therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound.
Baggio S; Pomini P; Galeone F; Presti F; Santi L; Raffaelli R; Franchi M
J Ultrasound Med; 2018 Sep; 37(9):2215-2223. PubMed ID: 29498074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
